Used as an alternative to mexiletine in the treatment of non-dystrophic myotonia, lamotrigine shows lasting efficacy in a new British study:
- it involved 37 patients with non-dystrophic myotonia, 23 with a mutation in the CLCN1 gene and 14 in the SCN4A gene,
- they received lamotrigine for an average period of 26 months,
- the treatment resulted in a significant improvement in symptoms, with a decrease in the myotonia score,
- however, 9 patients had to stop treatment due to headaches or severe skin rashes.
